Real World Evidence (RWE) - OHE

We found for

Summary Report of the OHE/EFPIA Antibacterial Roundtable

New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options

Exploring the Interdependency between Public and Charitable Medical Research

Incentives for R&D for New Antimicrobial Drugs

Priority Review Vouchers to Encourage Innovation for Neglected Diseases

New Drugs to Tackle Antimicrobial Resistance: EU Policy Options

Real World Evidence (RWE)

Enhancing the Benefits from Biomedical and Health Research Spillovers

Innovation in Medicines: Can We Value Progress?

Forward Together: Complementarity of Public and Charitable Research with Respect to Private Research Spending

Medical Research: What’s It Worth?

Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions

Economic Post-Launch Studies: Matching the Desirable with the Feasible

Institutions for Industrial Competitiveness in the International Pharmaceutical Industry

Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty

Capturing the Unexpected Benefits of Medical Research

The Road to Sustainability in the UK and German Biotechnology Industries

01
02
03

News & Insights

Latest Research & Publications

All Publications

We found for

Filter results by

Summary Report of the OHE/EFPIA Antibacterial Roundtable

New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options

Exploring the Interdependency between Public and Charitable Medical Research

Incentives for R&D for New Antimicrobial Drugs

Priority Review Vouchers to Encourage Innovation for Neglected Diseases

New Drugs to Tackle Antimicrobial Resistance: EU Policy Options

Enhancing the Benefits from Biomedical and Health Research Spillovers

Innovation in Medicines: Can We Value Progress?

Forward Together: Complementarity of Public and Charitable Research with Respect to Private Research Spending

Medical Research: What’s It Worth?

Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions

Economic Post-Launch Studies: Matching the Desirable with the Feasible

Institutions for Industrial Competitiveness in the International Pharmaceutical Industry

Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty

Capturing the Unexpected Benefits of Medical Research

The Road to Sustainability in the UK and German Biotechnology Industries

Share on Mastodon